HDL Apolipoprotein-Related Peptides in the Treatment of Atherosclerosis and other Inflammatory Disorders

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|16|28|3173-3184

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.16, Iss.28, 2010-09, pp. : 3173-3184

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inflammatory Disorders and Atherosclerosis: New Therapeutic Approaches

By  

Current Pharmaceutical Design, Vol. 17, Iss. 37, 2011-12 ,pp. : 4111-4120

Bentham Science Publishers

Access to resources Recommend Favorite

HDL and Inflammation in Atherosclerosis

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 1, 2004-03 ,pp. : 51-57

Bentham Science Publishers

Access to resources Recommend Favorite

Oxidative Stress, HDL and Atherosclerosis

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 7, Iss. 3, 2008-01 ,pp. : 158-165

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Hot Topic: Treatment of Atherosclerosis as an Inflammatory Disease)

By  

Current Pharmaceutical Design, Vol. 18, Iss. 28, 2012-09 ,pp. : 4265-4265

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 18, Iss. 28, 2012-09 ,pp. : 4311-4325

Bentham Science Publishers

Access to resources Recommend Favorite